The LUNGevity Foundation and 41 stakeholders aim to reduce cancer patients' confusion about in vitro diagnostic testing by implementing two consistent umbrella terms.
Results from the PROMPT registry presented at ASCO showed that 10 to 15 percent of women with variants in genes not linked to ovarian cancer had oophorectomies.
The company will offer a 32-gene polygenic score test to patients in the Osaka, Japan Nakanoshima Clinic, with reporting and patient support help from IxLayer.
The agency compiled the evolving list by drawing on information from drug labeling and the published literature and is asking stakeholders to provide feedback.
Blueprint provides 3,900 targeted single-gene and more than 200 panel tests covering 14 medical specialties, leveraging NGS and bioinformatics methods.
The company plans to make its PRS offering, currently used only in those who test negative for gene mutations, an option for all customers of European ancestry.
The score's developers also suggest that current guidelines for stroke prevention may not be sufficient for individuals at higher genomic risk for the condition.
Simulations suggested prostate cancer screening informed by polygenic risk scores is more cost effective and less prone to overdiagnoses than screening based on age alone.
PWNHealth will enable Stratify to offer its Prompt Personal Genetic Score prostate cancer genetic risk test directly to consumers with medical oversight.
